Overall, the findings of this study shed light on the critical molecular players and pathways driving trastuzumab resistance in HER2-positive breast cancer, offering valuable insights into potential therapeutic targets and strategies for overcoming treatment challenges associated with this aggressive subtype of breast cancer. Here, ERBB2 is linked to breast carcinoma.